Difference between revisions of "Procarbazine (Matulane)"
m |
|||
| Line 16: | Line 16: | ||
*[http://chemocare.com/bio/procarbazine.asp Procarbazine (Matulane) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/procarbazine.asp Procarbazine (Matulane) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/procarbazine.asp Procarbazine (Matulane) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/procarbazine.asp Procarbazine (Matulane) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/procarbazine-patient-drug-information Procarbazine (Matulane) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 7/22/1969: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| Line 22: | Line 25: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Alkylating agents]] | ||
| + | [[Category:DNA synthesis inhibitors]] | ||
| + | |||
| + | [[Category:Central nervous system (CNS) cancer medications]] | ||
| + | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
| + | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Mantle cell lymphoma medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1969]] | ||
Revision as of 16:13, 9 November 2014
General information
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Central nervous system (CNS) cancer
- CNS lymphoma
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma
Patient drug information
- Procarbazine (Matulane) patient drug information (Chemocare)[3]
- Procarbazine (Matulane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/22/1969: Initial FDA approval
Also known as
Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine, procarbazine HCl Chugaigai, procarbazine hydrochloride